MedTrace Logo

HD10 for Early Stages

NCT00265018 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 1370

Last updated 2011-07-29

No results posted yet for this study

Summary

This study is designed to find the optimum radiation dose and number of cycles for an ABVD chemotherapy combined with an involved field irradiation. It is to be tested whether the reduction from 4 to 2 cycles of ABVD and/or the reduction of the radiation dose from 30 to 20 Gy is feasible without a loss of efficacy.

Conditions

  • Hodgkin´s Lymphoma

Interventions

DRUG

Adriamycin

DRUG

Bleomycin

DRUG

Vinblastine

DRUG

DTIC

RADIATION

30 Gy IF-RT

RADIATION

20 Gy IF-RT

Sponsors & Collaborators

  • University of Cologne

    lead OTHER

Principal Investigators

  • Volker Diehl, Prof. · University of Cologne

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
FACTORIAL

Eligibility

Min Age
16 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1998-05-31
Primary Completion
2003-01-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00265018 on ClinicalTrials.gov